Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group (石药集团), has announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its financial structure [1]. Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1]. - The transaction is based on a comprehensive consideration of the seller's actual development status [1]. - The sale is expected to help optimize the seller's resource allocation and financial structure, allowing for a focus on core business and reduction of operational risks [1]. Group 2 - The target company primarily operates a full-media communication business platform, which is not part of the seller's core business [1]. - After the completion of the sale, the seller and the group will no longer hold any equity in the target company [1]. - This move is anticipated to contribute to the overall benefit of the group and facilitate high-quality development [1].
石药集团(01093.HK)附属2.3亿元出售国新汇金30%股权